Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$67.81 USD

67.81
4,294,477

-0.25 (-0.37%)

Updated Aug 15, 2025 04:00 PM ET

After-Market: $67.84 +0.03 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (152 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Veeva (VEEV) Application Completes Consent for First Patient (Revised)

by Zacks Equity Research

With this latest development, Veeva (VEEV) is likely to strengthen its portfolio of cloud-based offerings.

Urmimala Biswas headshot

Fed Eyes Faster Recovery in 2021: 3 MedTech Stocks to Buy

by Urmimala Biswas

MedTech stocks like INMD, BASI and SMLR are expected to maintain market-beating momentum in 2021.

Zacks Equity Research

Hologic (HOLX) Stock Moves -1.21%: What You Should Know

by Zacks Equity Research

Hologic (HOLX) closed the most recent trading day at $70.80, moving -1.21% from the previous trading session.

Zacks Equity Research

Veeva (VEEV) Application Completes Consent for First Patient

by Zacks Equity Research

With this latest development, Veeva (VEEV) is likely to strengthen its portfolio of cloud-based offerings.

Zacks Equity Research

HOLX vs. SMLR: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

HOLX vs. SMLR: Which Stock Is the Better Value Option?

Zacks Equity Research

Zimmer Biomet (ZBH) Shows Strong Core Growth Amid Weak EMEA

by Zacks Equity Research

For Zimmer Biomet (ZBH), the spin-off is an important step forward to its transition into a more streamlined business with a focus on more optimized resource allocation.

Zacks Equity Research

Medtronic (MDT) Gets FDA Nod for Revised Neuromodulation Labeling

by Zacks Equity Research

This latest development is expected to contribute to Medtronic's (MDT) pain therapy business in the coming months.

Zacks Equity Research

Why You Should Hold on to Illumina (ILMN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of products.

Zacks Equity Research

Encompass Health (EHC) Continues to Expand Presence in Texas

by Zacks Equity Research

Encompass Health (EHC) plans to construct a hospital in Texas for offering improved rehabilitative services, which highlights its efforts to bolster presence in the state.

Zacks Equity Research

Masimo's (MASI) EMMA Favored by New Study for Children

by Zacks Equity Research

The latest study highlights the importance of Masimo's (MASI) EMMA for children with tracheostomy, both in home-care settings and outpatient departments.

Kinjel Shah headshot

Buy These 7 Stocks With Low P/B Ratio to Boost Returns

by Kinjel Shah

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects. PVH Corp. (PVH), Honda Motor (HMC), Owens & Minor (OMI), ArcelorMittal (MT), Hologic (HOLX), ASE Technology Holding (ASX) and Goldman Sachs (GS) are good stocks to add.

Zacks Equity Research

NuVasive (NUVA), ISSGF Expand Tie-Up With Launch of 2 Studies

by Zacks Equity Research

NuVasive (NUVA) extends its long-term partnership with ISSGF and initiates additional clinical studies to transform the future of spine care.

Zacks Equity Research

HealthEquity (HQY) Q4 Earnings, Revenues Beat Estimates

by Zacks Equity Research

HealthEquity (HQY) delivers solid growth in HSAs and custodial assets in the fiscal fourth quarter.

Zacks Equity Research

Why You Should Add Surmodics (SRDX) to Your Portfolio Now

by Zacks Equity Research

Investor optimism is high on Surmodics (SRDX) stock, courtesy of its solid prospects.

Zacks Equity Research

Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

Zacks Equity Research

Baxter (BAX) Receives FDA Nod for AK 98 Hemodialysis Machine

by Zacks Equity Research

Baxter (BAX) gets FDA approval for its AK 98 Hemodialysis machine that offers a compact, portable and easy-to-use system for dialysis providers.

Zacks Equity Research

Here's Why You Should Retain Stryker (SYK) Stock Right Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.

Zacks Equity Research

Quest Diagnostics (DGX) Inks Agreement to Enhance Cardiac Care

by Zacks Equity Research

Quest Diagnostics (DGX) signs agreement with Zora to develop cardiovascular mortality prediction test with the help of the latter's patented ceramide-analysis technology.

Zacks Equity Research

Luminex (LMNX) Files EUA Application for New Respiratory Assay

by Zacks Equity Research

Luminex (LMNX) develops the combined assay to rapidly deliver clear solutions about respiratory infections from a single test.

Zacks Equity Research

Here's Why You Should Retain Allscripts (MDRX) Stock for Now

by Zacks Equity Research

Investor confidence is high on Allscripts (MDRX) stock, courtesy of solid prospects.

Zacks Equity Research

Cardinal Health (CAH) Inks Deal to Divest Cordis Business

by Zacks Equity Research

Cardinal Health (CAH) divests its Cordis business to focus on strategic growth areas.

Zacks Equity Research

Here's Why You Should Retain AmerisourceBergen (ABC) Now

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.

Zacks Equity Research

Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about robust demand for Hill-Rom's (HRC) product as well as its solid first-quarter fiscal 2021 results.

Zacks Equity Research

Hologic (HOLX) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Hologic (HOLX) has been struggling lately, but the selling pressure may be coming to an end soon

Zacks Equity Research

Hologic (HOLX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Hologic (HOLX) closed at $70.78 in the latest trading session, marking a -0.35% move from the prior day.